FGFR1 is amplified during the progression of in situto invasive breast carcinoma
Breast Cancer Research2012Vol. 14(4), pp. R115–R115
Citations Over TimeTop 10% of 2012 papers
Min Hye Jang, Eun Joo Kim, Yoomi Choi, Hee Eun Lee, Yu Jung Kim, Jee Hyun Kim, Eunyoung Kang, Sung‐Won Kim, In Ah Kim, So Yeon Park
Abstract
Amplification of HER2, C-MYC and CCND1 seems to play a role in the early development of breast cancer, but not in its progression. However, the increased frequency of FGFR1 amplification in invasive carcinomas compared with pure DCIS and in the invasive components of individual tumors, and its association with decreased disease-free survival, suggests a role for FGFR1 amplification in the progression of breast cancer including in situ-to-invasive transition, as well as initiation.
Related Papers
- → Fluorescent in situ hybridization on tissue microarrays: challenges and solutions(2007)52 cited
- → Quality aspects of the tissue microarray technique in a population‐based cohort with ductal carcinoma in situ of the breast(2008)21 cited
- → Feasibility of Using Tissue Microarrays for the Assessment of HER-2 Gene Amplification by Fluorescence In Situ Hybridization in Breast Carcinoma(2004)36 cited
- → Ten-Year Follow-up of Breast Carcinoma In Situ in Connecticut(1992)36 cited
- Papillomas of the breast. A histologic spectrum including atypical hyperplasia and carcinoma in situ.(1995)